The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma (HCC).
Jasgit C. Sachdev
Research Funding - Pfizer
Ahmed Y Javed
No relevant relationships to disclose
Alva Bowen Weir
No relevant relationships to disclose
Ronald I Korn
No relevant relationships to disclose
Shannon M Gulla
No relevant relationships to disclose
Ronald G Newbold
No relevant relationships to disclose
Matthew Smeltzer
No relevant relationships to disclose
Raymond U Osarogiagbon
Stock Ownership - Pfizer
Honoraria - Pfizer